Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Integrative Analysis of Gene Expression Patterns in Cutaneous Melanoma

FY 2018-19

Summary
Cutaneous melanoma (CM) is the deadliest form of skin cancer. Understanding the molecular features of this disease is essential to the development of more effective treatments. This study aims to dissect the heterogeneity of melanoma tumor gene expression between patients, because (1) pre-treatment gene expression has been shown to predict efficacy of treatments currently in use, and (2) gene expression changes in response to treatment may cause a cancer to become resistant to treatment. What makes this study unique is its attempt to examine the gene expression of individual cells that comprise a tumor, rather than the average gene expression of all cells in a tumor. The increased resolution will better our understanding of melanoma tumor gene expression and will inform us how well the constituents of pre-treatment gene expression predict response. The results will potentially allow (after further study) better tailored patient treatments and promote the development of novel treatments for patients who do not respond well to current treatments.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
408147
Name
Alkallas Rached
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Integrative Analysis of Gene Expression Patterns in Cutaneous Melanoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Deconvolution Of Tumor Composition; Genomics; Melanoma; Somatic Driver Mutations; Transcriptomics
Abstract
Cutaneous melanoma (CM) is the deadliest form of skin cancer. Understanding the molecular features of this disease is essential to the development of more effective treatments. This study aims to dissect the heterogeneity of melanoma tumor gene expression between patients, because (1) pre-treatment gene expression has been shown to predict efficacy of treatments currently in use, and (2) gene expression changes in response to treatment may cause a cancer to become resistant to treatment. What makes this study unique is its attempt to examine the gene expression of individual cells that comprise a tumor, rather than the average gene expression of all cells in a tumor. The increased resolution will better our understanding of melanoma tumor gene expression and will inform us how well the constituents of pre-treatment gene expression predict response. The results will potentially allow (after further study) better tailored patient treatments and promote the development of novel treatments for patients who do not respond well to current treatments.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Alkallas, Rached
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2018-19) | Canada Spends